Dt&무료 바카라 게임 establishes an advanced efficacy evaluation system for retinal and other ophthalmic diseases
[by Ji, Yong Jun] Dt&CRO announced on May 7 that it is providing global-standard services by leveraging a standardized efficacy evaluation system and advanced analysis capabilities, under the leadership of a study director with extensive expertise in non-clinical ophthalmic disease research.
The company is a full-service 무료 바카라 게임 trial contract research organization (CRO) that provides comprehensive support across the entire drug development process, encompassing non-무료 바카라 게임 trial analysis, bioequivalence testing, 무료 바카라 게임 trials, and licensing consulting. Dt&CRO delivers integrated solutions to facilitate full-cycle new drug development for Korean and international pharmaceutical and biotechnology companies. In particular, the company generates global-standard test data, drawing on its specialized expertise in efficacy testing, toxicity evaluation, and PK/PD analysis.
The company operates a range of 무료 바카라 게임 disease models, including dry and wet macular degeneration, optic nerve damage, dry eye, and glaucoma, and is characterized by its ability to overcome the technical challenges associated with tissue processing in rodent-based retinal disease models.
“Our goal is to broaden the depth and scope of non-무료 바카라 게임 efficacy testing across a range of therapeutic areas, including ophthalmic diseases,” a DT&CRO official said. “We are committed to reinforcing our role as a trusted partner in novel drug development by providing customized test designs and data analysis.”